Colchicine’s effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial
Authors:
- Andrew P. DemidowichADAndrew P. Demidowich
- CHI ConsortiumCCCHI Consortium
- Huizhi ZhouHZHuizhi Zhou
- Rongye ShiRSRongye Shi
- Poorani SubramanianPSPoorani Subramanian
- John TsangJTJohn Tsang
- Yasmine BelkaidYBYasmine Belkaid
Open Access
- 27 May 2020
- journal article
- research article
- Published by Springer Nature in International Journal of Obesity
- Vol. 44 (8) , 1793-1799
Abstract
Objective Recent clinical trials have demonstrated that colchicine may have metabolic and cardiovascular and benefits in at-risk patients; however, the mechanisms through which colchicine may improve outcomes are still unclear. We sought to examine colchicine’s effects on circulating inflammatory and metabolic molecules in adults with obesity and metabolic syndrome (MetS). Methods Blood samples were collected pre- and post-intervention during a double-blind randomized controlled trial in which 40 adults with obesity and MetS were randomized to colchicine 0.6 mg or placebo twice-daily for 3 months. Serum samples were analyzed for 1305 circulating factors using the SomaScan Platform. The Benjamini–Hochberg procedure was used to adjust the false discovery rate (FDR) for multiple testing. Results At baseline, age (48.0 ± 13.8 vs. 44.7 ± 10.3 years) and BMI (39.8 ± 6.4 vs. 41.8 ± 8.2 kg/m2) were not different between groups. After controlling for the FDR, 34 molecules were significantly changed by colchicine. Colchicine decreased concentrations of multiple inflammatory molecules, including C-reactive protein, interleukin 6, and resistin, in addition to vascular-related proteins (e.g., oxidized low-density lipoprotein receptor, phosphodiesterase 5A). Conversely, relative to placebo, colchicine significantly increased concentrations of eight molecules including secreted factors associated with metabolism and anti-thrombosis. Conclusions In adults with obesity, colchicine significantly affected concentrations of proteins involved in the innate immune system, endothelial function and atherosclerosis, uncovering new mechanisms behind its cardiometabolic effects. Further research is warranted to investigate whether colchicine’s IL-6 suppressive effects may be beneficial in COVID-19.Keywords
This publication has 28 references indexed in Scilit:
- Colchicine's effects on lipoprotein particle concentrations in adults with metabolic syndrome: A secondary analysis of a randomized controlled trialJournal of Clinical Lipidology, 2019
- Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trialDiabetes, Obesity and Metabolism, 2019
- Colchicine: an affordable anti-inflammatory agent for atherosclerosisCurrent Opinion in Lipidology, 2018
- The Global Epidemic of the Metabolic SyndromeCurrent Hypertension Reports, 2018
- Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary SyndromeJournal of the American Heart Association, 2015
- Association Between Colchicine and Risk of Diabetes Among the Veterans Affairs Population With GoutClinical Therapeutics, 2015
- Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic AgentsMolecular Therapy Nucleic Acids, 2014
- Effects of IL-6, adiponectin, CRP and metabolic syndrome on subclinical atherosclerosisClinica Chimica Acta, 2007
- Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes MellitusCirculation, 2005
- Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention StudyCirculation, 2003